Literature DB >> 20309641

Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression.

Kai-Ping Chang1, Huang-Kai Kao, Ying Liang, Ming-Hui Cheng, Yu-Liang Chang, Shiau-Chin Liu, Yu-Chi Lin, Tzu-Yin Ko, Yun-Shien Lee, Chia-Lung Tsai, Tzu-Hao Wang, Sheng-Po Hao, Chi-Neu Tsai.   

Abstract

BACKGROUND: Both activin A, a member of transforming growth factor beta superfamily, and its inhibitor follistatin have been shown to be overexpressed in various cancers. We examined the potential role of activin A and follistatin in tissue and blood samples from patients with oral squamous cell carcinoma.
METHODS: For activin A and follistatin, the expression of tissue samples from 92 patients was examined by immunohistochemical study, and the serum levels of blood samples from 111 patients and 91 healthy controls were measured by enzyme-linked immunosorbent assay.
RESULTS: We found that overexpression of immunohistochemically detected activin A was correlated with positive N stage, poor histological differentiation, and perineural invasion (P = 0.029, 0.002, and 0.014, respectively). In survival analyses, patients with oral squamous cell carcinoma, whose tumors overexpressed activin A, had a worse prognosis for overall survival and disease-free survival (P = 0.009 and 0.007). However, expression of follistatin in tumor was not correlated with overall survival or disease-free survival. Serum activin A and follistatin levels in 111 untreated patients were neither significantly different from those of 91 control samples nor associated with any clinicopathological manifestations. In vitro suppression of activin A expression in OC3 cells using specific interfering RNA-attenuated cell proliferation, migration, and invasiveness.
CONCLUSIONS: These findings suggest that activin A overexpression in oral squamous cell carcinomas is associated with patients' survival and may contribute to tumor progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20309641     DOI: 10.1245/s10434-010-0926-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

Review 1.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

2.  Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy.

Authors:  Yusuke Katayama; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Katsuhiko Masudo; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

Review 3.  The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.

Authors:  Michael Grusch; Michaela Petz; Thomas Metzner; Deniz Oztürk; Doris Schneller; Wolfgang Mikulits
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

4.  Comprehensive analysis of INHBA: A biomarker for anti-TGFβ treatment in head and neck cancer.

Authors:  Shunhao Zhang; Keyu Jin; Tianle Li; Maolin Zhou; Wenbin Yang
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-06

5.  Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.

Authors:  M A Hoda; J Münzker; B Ghanim; K Schelch; T Klikovits; V Laszlo; E Sahin; A Bedeir; A Lackner; B Dome; U Setinek; M Filipits; M Eisenbauer; I Kenessey; S Török; T Garay; B Hegedus; A Catania; S Taghavi; W Klepetko; W Berger; M Grusch
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

6.  Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response.

Authors:  Maria Antsiferova; Marcel Huber; Michael Meyer; Aleksandra Piwko-Czuchra; Tamara Ramadan; Amanda S MacLeod; Wendy L Havran; Reinhard Dummer; Daniel Hohl; Sabine Werner
Journal:  Nat Commun       Date:  2011-12-06       Impact factor: 14.919

7.  Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis.

Authors:  Andreia Bufalino; Nilva K Cervigne; Carine Ervolino de Oliveira; Felipe Paiva Fonseca; Priscila Campioni Rodrigues; Carolina Carneiro Soares Macedo; Lays Martin Sobral; Marcia Costa Miguel; Marcio Ajudarte Lopes; Adriana Franco Paes Leme; Daniel W Lambert; Tuula A Salo; Luiz Paulo Kowalski; Edgard Graner; Ricardo D Coletta
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

8.  Activin A balance regulates epithelial invasiveness and tumorigenesis.

Authors:  Grégoire F Le Bras; Holli A Loomans; Chase J Taylor; Frank L Revetta; Claudia D Andl
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

Review 9.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Cancers (Basel)       Date:  2014-12-30       Impact factor: 6.639

10.  Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma.

Authors:  Li-Jen Hsin; Huang-Kai Kao; I-How Chen; Ngan-Ming Tsang; Cheng-Lung Hsu; Shiau-Chin Liu; Yu-Sun Chang; Kai-Ping Chang
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.